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Early intervention with 
Bifidobacterium lactis NCC2818 
modulates the host-microbe 
interface independent of the 
sustained changes induced by the 
neonatal environment
Marie C. Lewis1, Claire A. Merrifield2, Bernard Berger3, Olivier Cloarec4, Swantje Duncker3, 
Annick Mercenier3, Jeremy K. Nicholson2, Elaine Holmes2 & Mick Bailey5
Inflammatory and metabolic diseases can originate during early-life and have been correlated with 
shifts in intestinal microbial ecology. Here we demonstrate that minor environmental fluctuations 
during the early neonatal period had sustained effects on the developing porcine microbiota and 
host-microbe interface. These inter-replicate effects appear to originate during the first day of life, 
and are likely to reflect very early microbiota acquisition from the environment. We statistically link 
early systemic inflammation with later local increases in inflammatory cytokine (IL-17) production, 
which could have important enteric health implications. Immunity, intestinal barrier function, host 
metabolism and host-microbiota co-metabolism were further modified by Bifidobacterium lactis 
NCC2818 supplementation, although composition of the in situ microbiota remained unchanged. 
Finally, our robust model identified novel, strong correlations between urinary metabolites (eg 
malonate, phenylacetylglycine, alanine) and mucosal immunoglobulin (IgM) and cytokine (IL-10, 
IL-4) production, thus providing the possibility of the development of urinary ‘dipstick’ tests to assess 
non-accessible mucosal immune development and identify early precursors (biomarkers) of disease. 
These results have important implications for infants exposed to neonatal factors including caesarean 
delivery, antibiotic therapy and delayed discharge from hospital environments, which may predispose 
to the development of inflammatory and metabolic diseases in later life.
Non-communicable diseases associated with metabolism and immunity are an increasing challenge for 21st cen-
tury medicine. Predisposition to many of these conditions appears to originate during early-life ‘programming 
events’1. This term refers to critical points of developmental plasticity where changes in environmental factors can 
have long-term effects on physiological development2, 3. Here, ‘environmental factors’ refers to anything exter-
nal to the individual including, for example, mode of birth delivery, nutritional and physiological status of the 
mother, siblings, nutrition and medication. One important link between such environmental factors and the 
development of later disease is the gut microbiota since it can be influenced by all of these factors and is a major 
driver for development of the host immunological4 and metabolic systems5. In laboratory animals, the pattern 
of early colonisation of bacterial species in the neonatal intestine influences both composition, and function of 
the adult microbiota6, 7 and we have previously demonstrated that the neonatal environment, and weaning diet, 
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exerts a sustained influence on the development of this microbiota and metabolic phenotype8. This sequential col-
onisation pattern9 is difficult to predict, control or measure in human populations but once developed the adult 
microbiome is considered to be relatively robust with individuals categorised as one of several different entero-
types10. Conditions including obesity, diabetes11 and inflammatory bowel disease12 often correlate with specific, 
atypical microbiota composition/profiles which may originate in childhood13. Thus, modulation of microbial 
ecosystems can occur early in humans, perhaps when the composition is less stable and can be stretched beyond 
an ‘elastic limit’ where the changes become permanent14. By analogy, the changes in host metabolism and immu-
nity resulting from this early microbial colonisation are likely to lead to long lasting imprinting. The dynamic 
evolution of the intestinal ecosystem in the early-life stages may represent a window of opportunity to influence 
the development of the microbiota, and therefore the immune and metabolic systems, through the administration 
of specific bacterial strains.
Although current literature links the immune system, metabolism, and the intestinal microbiota15–19, the 
molecular interactions and pathways involved in this cross-talk are complex and poorly characterized. However, 
the existence of these links does suggest that it is feasible to identify biomarkers in accessible biofluids, such as 
metabolites in urine, which may correlate with changes in less accessible sites, such as immune responses in the 
intestinal mucosa. Such biomarkers could be effective in the early detection of disease, monitoring disease devel-
opment and for quantifying the efficacy of therapeutic intervention. There is increasing interest in identifying 
biomarkers of low grade inflammation which has been implicated in multiple disease processes including insulin 
resistance, type II diabetes and cardiovascular diseases20–23, as well as many gut disorders24, 25. Further under-
standing of microbiota, metabolic and immune interactions could lead to the identification of novel biomarkers 
of immune development, and status, and contribute to the development of stratified and personalised medicine.
Pigs are valuable comparative models for humans26 since they share many features of gastrointestinal physiol-
ogy, immunology, metabolism, microbiology and diet27–29. Here we use the neonatal piglet to evaluate the effect 
of Bifidobacterium lactis NCC2818 subsp. lactis (B. lactis NCC2818) (CNCM I-3446), previously documented for 
its probiotic properties in human infants30–34, on the intestinal microbiota, metabolism and mucosal immune 
system when supplemented from birth. Our experimental design allowed us to identify effects of environmental 
variations in the immediate post-natal period on later immune, metabolic and microbial parameters. Despite 
considerable variation between our two experimental groups, we established that probiotic supplementation leads 
to robust changes in the host response that can be evidenced beyond those induced by environmental factors. 
Finally, we identify immune-metabolic correlations with the aim of exploring potential novel (surrogate) bio-
markers in this tractable model species.
Results
Early B. lactis NCC2818 administration ameliorates inter-batch differences in intestinal barrier 
integrity. Supplementation with B. lactis NCC2818 was associated with increased expression of the tight-cell 
junction (TCJ) associated protein ZO-1 in the epithelium of the distal jejunum (p = 5.7 × 10−5, Fig. 1a, c and e). 
There were significant differences in expression both of ZO-1 and E-cadherin between the replicate batches, batch 
1 expressing more ZO-1 and E-cadherin (p = 0.013 and p = 0.032 respectively) than batch 2 (Fig. 1b, d and f).
Batch effects detected at 35 days old are present from 1 day after birth. In order to determine 
whether batch differences arose during the feeding of probiotic or before the introduction of any experimental 
intervention, serum samples taken from piglets at 1 day old, before the start of the intervention, were analysed. 
Significant differences were observed in the serum between animals in different replicate batches from the start 
of the experiment (Fig. 2a). Even at 1d old, batch 1 had significantly lower levels of serum N-acetylglycoproteins 
(NAG), histidine, phenylalanine, pyruvate, myo-inositol and significantly higher levels of isoleucine, choline and 
glucose than animals in batch 2 (Fig. 2b). At 21d, batch differences were still present, although the metabolites 
involved had changed: the significant higher level in serum choline in batch 1 at 1d was conserved, while glucose, 
galactose and formate levels were lower in batch 1 but higher in batch 2 (Fig. 2c). Differences in serum metab-
olites between batches were reduced after weaning (21d), and at the end of the experiment (35d), there were no 
significant differences observed in serum between the two batches. In contrast, no significant effect of B. lactis 
NCC2818 supplementation on the metabolic profile of serum was observed at any point during the experiment 
(data not shown).
Mucosal cytokines synthesis is affected by both experimental batch and early supplemen-
tation with B. lactis NCC2818 while early inflammatory markers predict later cytokine syn-
thesis. Functionally, supplementation with B. lactis NCC2818 was linked to a significant decrease in IL-4 
production from MLN, and significantly increased production of IL-4 from colon, interferon gamma (IFNγ) 
from caecum and IL-10 from the JPP (Fig. 3a), Effects associated with probiotic supplementation were detected 
despite the presence of underlying differences in the production of these proteins between the two experimental 
batches: piglets in batch 2 had significantly increased IL-10 secretion from both the caecum and colon compared 
to batch 1 counterparts (Fig. 3b). The unprocessed cytokine data are available as Supplementary Fig. 1.
The observation that markers of an acute phase response (NAG) were relatively increased in the animals in 
batch 2 at 1 day old, coupled with the increased regulatory cytokine expression in the large intestine at 35 days old 
in the same animals led us to postulate if early inflammatory response could predict later cytokine production. 
An O-PLS model was performed using the relative concentration of NAG as the Y matrix and the 35 day cytokine 
profile as the X-matrix. The results (Fig. 3d) demonstrate a statistical correlation between increasing levels of 
NAG at 1 day and increasing levels of colonic and caecal IL-10 and distal small intestinal IL-17 at 35 days. The 
distribution of animals from the different batches in the scores plot (Fig. 3c) from this model indicates that this is 
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not simply an artefact of batch. In fact, animals supplemented with B.lactis NCC2818 induced a more pronounced 
tolerogenic cytokine response linked to increased 1 day NAG.
Supplementation with B. lactis NCC2818 reduced inter-batch variation in mucosal antigen 
expression. Principle Component Analysis (PCA) of quantitative immunohistology identified two compo-
nents accounting for more than 40% of the variance in expression and co-localisation of CD4, CD16, MHCII and 
the MIL11 epitope (gut capillary endothelium) in colonic mucosa. Both supplementation with B. lactis NCC2818 
and experimental batch were associated with clustering in the PCA scores (Fig. 4g). Examination of the loadings 
Figure 1. Expression of tight-cell junction proteins is increased by B. lactis NCC2818 supplementation and 
by batch. Quantitative immunohistology of ZO-1 and E-cadherin staining in jejunal epithelium in response to 
treatment (a) or related to batch (b). Representative images of ZO-1 staining (red) in the treatment group (c) 
and control group (e), and E-cadherin staining (green) in batch 1 (d) and batch 2 (f) in the villus tip. n = 6; Error 
Bars = SEM.
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associated with these two components showed that supplementation with B. lactis NCC2818 was linked to differ-
ences in the presence of professional antigen-presenting cells (co-expression of CD16 and MHCII), presentation 
by these cells to CD4+ T-cells (co-expression of CD16, MHCII and CD4) and recruitment of endothelial cells to 
this interaction (CD16, MHCII, CD4, MIL11). Additionally, supplementation with B. lactis NCC2818 resulted in 
less inter-batch variation between animals than in the control group, where the separation of animals due to batch 
was more apparent. The unprocessed antigen presentation data are available as Supplementary Fig. 2.
Probiotic administration and experimental batch influence gut-microbial co-metabolism. 
Dietary supplementation with B. lactis NCC2818 resulted in a significant decrease in urinary excretion of phe-
nylacetylglycine (PAG), while formate excretion increased (Fig. 5a). Experimental batch significantly influenced 
the urinary metabolic profile at 35d: urinary excretion of metabolites involved in methyl donation and choline 
metabolism (trimethylamine, betaine, sarcosine, dimethylglycine) were significantly higher in batch 2 than in 
batch 1, as were TMAO, alanine and 3-hydroxyisovalerate. In addition, urinary malonate and allantoin were 
significantly higher in batch 1 compared to batch 2. Urinary mannitol excretion was the only metabolite affected 
by both batch and probiotic intervention, being higher in batch 2 and decreased by supplementation with B. lactis 
NCC2818 (Fig. 5a).
Figure 2. Batch effects are observed in the metabolic profile of serum at 1d. (a) Serum was analysed by 
1H NMR spectroscopy and a pairwise comparison was made by O-PLS-DA (uv scaling), between the two 
experimental batches (n = 6) and the mean of the cross-validated scores (Tcv) from each model (+/− standard 
deviation) are plotted at 1, 21, 28 and 35 days. Post-weaning period depicted by blue shading. (c) Significant 
correlation coefficients (r > +/− 0.6) were extracted from these pairwise models and displayed as a heatmap 
for the model at 1d (b) and at 21d (c). Metabolites coloured in increasing shades of purple are significantly 
increased in batch 2 and metabolites ordered by metabolic pathway. Abbreviations: AA–amino acid; CHO–
carbohydrate; NAG–N-acetyl glycine.
www.nature.com/scientificreports/
5Scientific RepoRts | 7: 5310  | DOI:10.1038/s41598-017-05689-z
Interestingly, there were no significant effects of B. lactis NCC2818 supplementation on the composition of the 
colonic microbiota at 35d, either in the luminal contents or the mucosa (data not shown). However, significant 
differences in the colonic bacterial populations were observed between experimental batches (in both treated and 
Figure 3. Mucosal cytokines synthesis is affected by both experimental batch and early supplementation with 
B.lactis NCC2818 while early inflammatory markers predict later cytokine synthesis. Back-scaled correlation 
covariance plots derived from a pairwise O-PLS-DA model comparing the effect of B. lactis NCC2818 
supplementation on cytokine production in immunological tissues (a). The bars pointing upwards denote 
cytokines that are relatively increased in animals supplemented with B.lactis NCC2818 from 1 day (n = 6)–an 
increasing colour intensity of red depicts the strength of this association (r2) and model statistics can be seen 
in the upper left hand corner. The experimental batch significantly affected 35 day cytokine production (b); the 
bars pointing upwards denote those cytokines that are relatively increased in batch 2 (n = 6). The cross-validated 
scores of O-PLS model using 24-hour serum N-acetylglycoproteins as a Y variable to predict 35 day cytokine 
production is shown in (c) with the legend above. Figure (d) depicts the corresponding loadings plots with bars 
above the axis representing cytokines associated with a relatively higher level in 1 day serum NAG.
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control groups), particularly in relation to Clostridia and Bacteroidia (Fig. 5b). The most pronounced differences 
between the two batches were reproducibly observed with both luminal and mucosal microbiota, strongly raising 
confidence in this observation.
Urinary metabolite concentrations are significantly correlated to immunological parameters. 
Immunoglobulin and cytokine parameters from all piglets, irrespective of batch and whether they received 
B. lactis NCC2818 supplementation, were compared to urinary metabolic profile and a number of significant 
Figure 4. Reduced inter-batch variation in mucosal antigen expression in animals supplemented with B.lactis 
NCC1818. Representational images of CD4 (a), CD16 (bone-marrow-derived APC) (b), MIL11 (intestinal 
epithelium) (c) and MHCIIDR (d) staining in colonic tissue of a control piglet. Representational image of 
co-staining with CD16 (red), MIL11 (green) and MHCIIDR (blue) (e) and co-staining with CD4 (red), CD16 
(green) and MIL11 (blue) (f). Co-localisation of MHC class II with, endothelial cells (MIL11) and CD4+ T-cells 
determined by principal component analysis. Principal component 1 was not associated with either treatment 
(n = 6) or batch (n = 6). Principal components 2 and 3 for each piglet, identified by treatment (colour) and batch 
(symbol).
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correlations were identified across this immuno-metabolic interface (Fig. 6). These included positive corre-
lations between colonic IL-10 synthesis and urinary metabolites associated with methyl donation (sarcosine, 
betaine and trimethylamine) (p = 0.01), and between malonate (associated with the TCA cycle) and colonic 
IgM (p = 0.008). Interestingly, this analysis also identified significant negative correlations between methyl 
donation-associated metabolites and caecal IL-4 (p = 0.02) and IgM (p = 0.03). Further, metabolites linked to 
the intestinal microbiota were significantly correlated with immune parameters, consistent with the microbiota 
influencing immune development: hippurate was negatively correlated with caecal IL-4 (p = 0.02) while PAG 
was positively correlated with colonic IgM (p = 0.008). The unprocessed IgM data are available as Supplementary 
Fig. 3.
Figure 5. Probiotic administration and experimental batch influence gut-microbial co-metabolism, but only 
batch is associated with changes in the composition of the microbiota. (a) Correlation coefficient heatmap 
derived from 2 pairwise O-PLS-DA models comparing the effect of B. lactis NCC2818 supplementation (n = 6) 
to controls (n = 6) and comparing experimental batches (n = 6). Metabolites are ordered by their biological 
similarity and those coloured in increasing shades of purple are significantly increased in batch 2 or after B. 
lactis NCC2818 supplementation, while those in increasing shades of blue are relatively increased in batch 1 
or the control group. (b) Volcano plot derived from a pairwise O-PLS-DA model comparing bacteria at family 
level between batches. Suffix ‘_C’ denotes colonic content and ‘_M’ colonic mucosa; the red dots mark the 
coordinates of each family’s correlation (r2) and covariance. The points in the upper left quadrant denote those 
bacterial families that are increased in batch 1 whereas those points present in the upper right quadrant are 
relatively increased in batch 2. Those points above the red dashed line (at 0.4) are considered to be above the 
significance threshold. Abbreviations: AA–amino acid; TMAO–Trimethylamine-N-oxide.
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Discussion
Supplementation with B. lactis NCC2818 from the first day of life had significant effects on intestinal barrier 
function, development of the mucosal immune system and metabolic function in these outbred piglets. Batch 
effects are a consistent occurrence in animal studies and reflect the inconsistencies observed within free-living 
human populations. The observation that the overall effects of probiotic supplementation appear robustly sus-
tained across all domains, even in the presence of a significant, additional effect of experimental batch, is an 
encouraging finding.
The influence of supplementation with B. lactis NCC2818 on intestinal barrier function was apparent in two 
separate platforms. The cytoplasmic protein ZO-1 associates with claudins in the tight-cell junctions, contributing 
to epithelial barrier integrity. Mannitol is not produced endogenously or by the microbiota, and is normally too 
large to cross the intestinal epithelial barrier. Its appearance in urine therefore is associated with transfer of dietary 
mannitol across an intestinal epithelium with decreased integrity, as occurs around weaning. Supplementation 
with B. lactis NCC2818 increased expression of epithelial ZO-1 and decreased excretion of urinary mannitol even 
in the presence of differential mucosal barrier integrity between replicates. Reduced epithelial barrier integrity is 
associated with the development of intestinal inflammatory conditions, promotion of translocation of opportun-
istic pathogens into the portal venous system and may compromise mucosal healing. However, the link between 
intestinal permeability and health has been comprehensively reviewed elsewhere35. In humans, administration 
of B. lactis NCC2818 to newborn infants was shown to promote immune development31 and response to vacci-
nation32 whilst in preterm infants, B. lactis NCC2818 was shown to decrease intestinal permeability36. Here we 
provide further evidence that B. lactis NCC2818 is able to reinforce intestinal barrier integrity in the first days of 
life irrespective of the starting status.
Although B. lactis NCC2818 had no discernible effects on the composition of the microbiota at the family 
level, it did affect the urinary host-microbial metabolic profile (e.g. increased phenylacetylglycine and decreased 
formate), indicating that supplementation influenced the metabolic function of the microbiota, rather than 
the composition, at least at this taxonomic resolution and sequencing depth. The host and microbiome com-
municate via several distinct axes and the alteration in host-microbial metabolism we observed could have 
occurred through direct interactions with the microbiota or, indirectly, through modulation of the immune 
system. Consistent with the latter, supplementation with B. lactis NCC2818 resulted in changes in multiple 
Figure 6. Urinary metabolite concentrations are significantly correlated to immunological parameters. 
Heatmap derived from 4 separate O-PLS models linking the urinary metabolic profile to immunological 
parameters (n = 12). Metabolites are grouped by biological similarity. †Denotes a tentative assignment, PAG–
phenylacetylglycine, AA–amino acid, TCA–tricarboxylic acid. Writing in bold to the left denotes putative 
metabolic pathway involvement (n = 12).
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immunological read-outs, including local production of immunoglobulins and cytokines in multiple tissues, 
and expression of antigen-presenting cell function in colonic mucosa. However, the results do not clearly indi-
cate preferential effects on specific immunological pathways: in different tissues, increases were seen in the Th1 
cytokine IFN-γ, the Th2 cytokine IL-4 and the regulatory cytokine IL-10. Nevertheless, supplementation with B. 
lactis NCC2818 was shown to reduce the differences in antigen presentation observed between the two batches.
Batch effects are a consistent occurrence with animal studies and are often attributed to differences in the 
environment in which the study takes place. However, such batch effects are likely to represent the kind of 
variation seen in the human populations which are the target of the interventions developed in animal trials. 
Understanding the sources of variation other than genetic background could improve the success rate of trans-
lation from animal trials to humans. In the experiments here, it was possible to identify some of the sources of 
batch variation. Since the environments in which the individually housed piglets were maintained from day 2 
were highly controlled, and since the batch differences were observed prior to entry into this environment, it is 
unlikely that the variation developed during the course of the nutritional intervention. This is further supported 
by the observation that differences between batches in serum metabolic profile on entry into the trial disappeared 
after 21 days, indicating convergence, although urine profiles were still different at 35 days. It seems more likely 
that the source of the observed batch effects was differences in the environments of the piglets either in utero or, 
since the sows were co-housed and each batch was derived from several sows, more likely in the first day after 
birth. Intriguingly, some of these differences were associated with inflammation (NAG, and histidine) although 
no observable health differences were identified between the batches either on the farm (maternal or piglet) 
or later in the isolator (piglet) and all animals survived and furthermore appeared healthy throughout. Serum 
from piglets in batch 2 contained significantly higher levels of these inflammation-associated metabolites and, 
although we cannot be sure of intestinal permeability at this time point, later measurements of epithelial cell-cell 
adhesion molecules demonstrated reduced intestinal barrier function in these piglets and it is possible that these 
two findings are linked. Inflammation is most often studied in adulthood, but there is growing evidence that the 
early life environment has long-term, independent effects on immune regulation37 and inflammation, and is 
linked to exaggerated inflammatory responses to in vitro bacterial challenge38, 39. Importantly in this study, the 
animals which had a more ‘inflammatory’ phenotype at day 1 went on to secrete significantly increased levels of 
jejunal IL-17 at 35 days (and to a lesser extent in colonic tissue), despite being reared in the same high-hygiene 
environment. Increased expression of Il-17-producing intestinal-specific Th17 phenotypes have been causally 
linked to several inflammatory gut disorders40, 41 and are being progressively implicated in the gut-brain axis and 
ill health outside the gut, including autoimmune neuroinflammation42. However these animals also secreted more 
of the regulatory cytokine IL-10 at 35 days in large intestine sites (caecum and colon) indicating further long-term 
immunomodulation driven by early life events. Both batch and B. lactis NCC2818 supplementation had distinct 
effects on host microbial-metabolic interaction, with urine and serum providing a more focused window of effect 
at different time points. We have observed previously43 that serum contains fewer microbial derived compounds 
in comparison to urine and that it is under tighter homeostatic control than urine, which is strongly influenced by 
environmental factors. This current study reinforces the idea that subtle environmental variation is far more likely 
to be detected by analysing the urine than the serum in the context of the microbiome and nutrition.
While both batch and treatment effects were associated with alterations in host-microbial metabolism, 
only batch was linked directly to modifications in the composition of the gut microbiome, suggesting that the 
effect observed here was linked to initial microbial colonisation during the first day of life. The differences in 
the microbiome identified between the batches were apparent even at the family level. There was a significantly 
larger population of members of the Ruminococcaceae family in batch 1 piglets compared to batch 2. Members 
of this family are known to reside in the mucosal folds of the mammalian colon and populations of microbes in 
this location remain largely uncharacterized44. However, several studies have linked reduced intestinal coloni-
sation by members of the Ruminococcaceae family to chronic intestinal disorders such as IBD in humans45–47. 
Microbiome analysis of intestinal mucosal scrapings also showed that batch 2 piglets harboured higher levels of 
Bacteroidia Porphyromonadaceae family members. While the direction of causality is unclear, it has been shown 
that Porphyromonas were enriched in human colorectal tumours compared to healthy controls and may be impli-
cated in increased risk of disease development48. It is important to note that these families constitute normal 
commensal intestinal bacteria and their presence or absence is not a biomarker of disease, but instead the link is 
to their relative abundance, and possibly their activity.
In summary, our results demonstrate that supplementation with B. lactis NCC2818 from 1 day old improved 
intestinal barrier function and had significant effects on the development of the mucosal immune system and 
metabolic function. However, these effects were superimposed on a background of sustained batch differences. 
The experimental design, and the observed differences at one day, indicate that these batch effects are most likely 
attributable to differences in acquisition of intestinal microbiota immediately after birth, and that these differ-
ences may then determine subsequent development of metabolic and immunological function. Consequently, we 
suggest that the early life environment, and development of the early microbiota, should be taken into account 
during the design and interpretation of animal trials. Furthermore, understanding the causes of batch varia-
tion may contribute to improving translation from animal models to human populations. Nevertheless, the 
physiological effects of very early supplementation with B. lactis NCC2818 were consistent across both batches 
and therefore, in the longer term, could offer the potential to improve outcomes for ‘at-risk’ infants which have 
undergone early-life events linked to aberrant patterns of intestinal colonisation, for example caesarean birth or 
antibiotic therapy. Finally, irrespective of batch and probiotic treatment, robust links between mucosal immu-
nological parameters and the urinary metabolic profile are demonstrated by the correlations we observed in this 
model: these associations raise the possibility that accessible metabolic profiling may provide valuable biomarkers 
to assess previously inaccessible parameters including the function of the microbiota and associated intestinal 
immune system in future clinical trials.
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Materials and Methods
Animals. Animal study was conducted at the School of Clinical Veterinary Sciences (University of Bristol) and 
performed according to ethical guidelines under a UK Home Office License, approved by the University of Bristol 
ethical review group. Six healthy, large white hybrid, out-bred sows (2–3 parity) were chosen randomly from 
a commercial herd of 250, all housed in a single barn. Three sows (batch 1) were artificially inseminated using 
semen from 1 boar and 8 weeks later 3 additional sows (batch 2) were artificially inseminated using semen from 
the same boar. Shortly before giving birth, batch 1 sows were relocated to the farrowing unit and 2 healthy piglets 
from each of the resulting litters (n = 6) were taken to an isolator facility at 1 day old after receiving standard hus-
bandry iron via an IP injection, but no antibiotics. This highly controlled, standardised environment (SPF, HEPA 
filtered, positive pressure) was thoroughly cleaned and fumigated with formaldehyde gas (Alphagen Prills pellets, 
Antec AH Int., Sudbury, UK) before each experiment. The piglets were housed together within this isolator for 1 
day while they learnt to drink a pig adapted bovine milk-based formula (Piggimilk®,Volac Ltd, Lincolnshire, UK, 
supplementary table 1), similar to that given to human infants (with or without probiotics accordingly). At 2d, 
the piglets were moved to individual units within the isolator before being sibling- and gender-matched into two 
groups at weaning (21d). The piglets were weaned onto an egg-based solid (slurry) diet, which was nutritionally 
balanced and supplemented to meet their requirements (Volac Ltd, Sleaford, Lincolnshire, UK, supplementary 
table 1). One group received B. lactis NCC2818 intervention in the form of spray-dried culture mixed into the 
formula and weaning feed at a concentration of 4.2 × 106 colony forming units (CFU)/g, equivalent to 2 × 109 
CFU/kg metabolic wt/day). The remaining group (control group) received identical diets (same batch of feed), 
but without the probiotic and a biosecurity barrier was established to avoid crossover between the two groups. 
Four weeks after batch 1 sows vacated the farrowing unit, batch 2 sows entered the same unit in preparation for 
birth. Again, 2 healthy piglets were removed from each of the 3 batch 2 sows at 1 day old and underwent exactly 
the same process as piglets in batch 1. This experimental design (Fig. 7) resulted in n = 6, gender-matched, lit-
ter-matched piglets in each treatment group (Control and probiotic) and n = 6 gender-matched piglets in each 
replicate (batch 1 and batch 2). The experimental design is detailed in Supplementary Figure 4. The number of 
piglets used was based on our previous experiments37, 43, 49–53 where using litter as a factor during the statistical 
analysis reduces the number of animals required.
All piglets were bled by venipuncture at 1d (immediately following removal from the mothers), 21d (immedi-
ately before weaning) and 28d old and samples stored at −80 °C. At 35d, piglets were euthanised with an overdose 
of pentobarbitone (Euthatal®, Merial Animal Health, Essex, UK). At post-mortem, heart blood was obtained 
and serum was snap-frozen, along with urine aspirated directly from the bladder, in preparation for metabo-
nomic profiling. Colonic (descending; adjacent to the colo-rectal junction) contents and mucosa were removed 
and snap-frozen for 16S pyrosequencing. Mesenteric lymph node (MLN), jejunal Peyer’s patch (PPs), proximal 
and distal jejunum (not containing PPs), splenic tip, caecum tip and the ascending portion of the spiral colon 
were removed for organ fragment culture (OFC). Additional colonic and distal jejunum samples from the same 
locations were mounted in OCT embedding matrix, snap frozen and then stored at −80 °C for later fluorescence 
immunohistological analysis.
Sample Preparation for 1H NMR. Serum. Blood serum samples were prepared by the addition of 350 µl 
0.9% saline solution containing 10% D2O (to act as a spectrometer field frequency lock) to 200 µl of serum. This 
mix was then vortexed, centrifuged at 12,000 g for 20 minutes and transferred into 5 mm outer diameter NMR 
tubes in preparation for analysis.
Figure 7. Animal trial: Schematic representation of the experimental setup depicts batch 1 (n = 6), batch 2 
(n = 6), treatment (supplemented with B. lactis NCC2818 from 1 day old, n = 6) and untreated groups (no 
B. lactis NCC2818, n = 6). Piglets were fed formula milk before being weaned at 21 days (denoted by red 
arrow) onto an egg protein-based diet until the experiment concluded at 35 days. A detailed schematic of the 
experimental design is available in the supplementary data (Supplementary Fig. 1).
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Urine. Urine samples were prepared by the addition of 220 µl of a 1 mM 3-trimethylsilyl-1-[2,2,3,3,−2H4] propri-
onate (TSP), 3 mM sodium azide (NaN3) and 80/20 (v/v) H2O/D2O phosphate buffer solution (pH 7.4) to 440 µl 
of urine. This mixture was vortexed, left to stand for 20 minutes and then centrifuged at 12,000 g for 20 minutes. 
Six hundred µl of the supernatant was transferred to 5 mm outer diameter NMR tubes54.
1H NMR Spectroscopy. Serum. Serum samples were collected longitudinally throughout the experiment 
as previously described. The 1H NMR metabolic profiles of these samples were acquired on an Avance 600 MHz 
NMR spectrometer (Bruker Biospin) and spectra were collected using a BACS autosampler with a Bruker 5 mm 
TXI triple resonance probe at 300 K. 256 scans (16 dummy scans) were collected into 64 k data points over a 
20 ppm spectral width using a Carr-Purcell-Meiboom-Gill (CPMG) spin echo sequence, incorporating an echo 
time of 200μs to highlight contributions from low-molecular weight moieties.
Urine. The metabolic profile of urine from each of the piglets (collected at 35 days) was obtained by NMR 
spectroscopy. All spectra were acquired on an Avance 600 MHz NMR spectrometer (Bruker Biospin) and spectra 
were collected using a BACS autosampler with a Bruker 5 mm TXI triple resonance probe at 300 K. 256 scans (16 
dummy scans) were collected into 64 k data points over a 20 ppm spectral width using the first increment of a 
standard one dimensional experiment with water presaturation during the relaxation delay of 2 s and during the 
mixing time of 100 ms.
Metabolite Identification. Metabolites were identified by further 2D NMR experiments (J-RES, TOCSY, 
HSQC) as described previously43 for structural assignment, by using extant literature43, 55 and by using data-
bases such as the Human Metabolome Data Base (HMDB): http://hmdb.ca/ 56, 57 and the Biological Magnetic 
Resonance Data Bank (BMRB) http://www.bmrb.wisc.edu/, along with SBase/Amix (Bruker BioSpin 2006) and 
NMR Suite (Chenomx, Edmonton, Canada).
Quantification of the gastrointestinal microbiota using 16 S DNA pyrosequencing. DNA was 
extracted from faecal and colonic content samples using the Qiagen EZ1 kit (Qiagen, Germany) after mechanical 
disruption as follows: for colon content, 100 mg of material was placed in lysozyme buffer (50 mg/ml) with 0.3 g 
of glass beads, disrupted in a bead-beater at maximal speed for 1 min and then incubated at 37 °C for 15 min; 
for colon tissue, 200 mg were placed in Lysing Matrix Tubes D with lysozyme buffer and homogenised with 
FastPrep-24 (MP Biomedicals, Solon, OH 44139), 2 × 20 sec speed 6, with 5 min break. After centrifugation 
(5 min, 200 g), supernatant was transferred into tubes with 0.3 g of glass beads, disrupted in a bead-beater at 4 °C 
at maximal speed for 1 min and then incubated at 37 °C for 15 min.
The V1, V2 and V4 regions of the 16 S genes contained in the DNA extracts were amplified, sequenced in 
multiplex using the GS FLX System (Roche, Switzerland), and analyzed as previously described58, except for the 
confidence threshold of the RDP Classifier which was set to 60%, as in previous published studies59, 60. All data 
analysis was conducted on the mean relative proportion of bacteria (%). Due to the high proportion (~35%) of 
unclassified bacteria of pig origin identified at the genus level, we have used the family level as a trade-off between 
the coverage of the microbial population and the depth of taxonomical analysis.
Organ Fragment Culture. As previously described61, 4 cm2 of the intestinal samples and 1 cm3 of MLN and 
spleen were vigorously washed in Ca2+ and Mg2+-free Dulbecco’s PBS (Sigma) containing 0.5 μM EDTA (Sigma), 
1 M HEPES (Invitrogen, Paisley, UK) and 50 μg/ml gentamycin (Gibco, Paisley, UK), followed by 3 further washes 
in Dulbecco’s PBS containing 1% HEPES and 50 μg/ml gentamycin before being placed in RPMI1640 (Sigma, 
Gillingham. UK) containing 10% FCS (PAA, UK), 200 mM L-Glutamine (Invitrogen, Paisley, UK), 20U/ml strep-
tomycin/penicillin (Invitrogen) and 50 μg/ml gentamycin (complete medium). Intestinal tissues were cut into 
3 mm2 fragments while spleen and MLN were cut into 2 mm3 fragments and one fragment was placed in each of 
6 individual wells (Corning Incorporated, UK) containing 1 ml of complete medium. Cultures were incubated at 
37 °C, 5% CO2, 100% humidity for 96 h, after which they were frozen at −20 °C. The plates were thawed and the 
spent medium from each of the 6 duplicate wells was pooled and refrozen for later analysis.
Cytokine production in organ fragment cultures. Supernatants from OFCs were analysed by ELISA for 
cytokine production using Swine IFNγ, IL-4 and IL-10 Cytoset kits (Biosource, Paisley, UK) and interleukin-17 
was detected using the Swine IL-17 VetSet (Kingfisher Biotech, Saint Paul, Minnesota, US). All kits were used in 
accordance with the manufacturer’s protocols. Absorbance was read at 450 and 650 nm and concentrations of 
cytokine were determined by interpolation of samples onto the standards.
Total IgM production in organ fragment cultures. Catching ELISA was carried out to determine total 
IgM in spent medium from OFCs. Briefly, 96 well microplates were coated with affinity purified goat anti-pig 
IgM (Bethyl Laboratories, Montgomery, Texas, USA). Serial dilutions of serum samples and reference standard 
were added to coated plates and incubated for 2 h at room temperature. Bound immunoglobulins were detected 
using isotype-specific monoclonal antibodies (anti-pig IgM K52.1C3, from Serotec) followed by HRP-conjugated 
goat-anti-mouse IgG1. Concentrations of immunoglobulin subclasses were determined by interpolation of sam-
ples onto the reference standards.
Fluorescent immunohistology, image capture and analysis. Serial, 5 μm sections of the ascend-
ing portion of the spiral colon and from the distal jejunum were cut using a Model OTF cryotome (Brights 
Instrument Company Ltd., Huntingdon. UK). Sections were air dried for 24 h then fixed by immersion in acetone 
for 15 min. Slides were dried prior to storage at −80 °C.
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Quantification of jejunal tight cell junction (TCJ) associated proteins was carried out using: rabbit anti-mouse 
Zona Occludin-1 (ZO-1, Zymed, clone 61-7300) and mouse anti-rat E-cadherin (clone DECMA-1, IgG1), both 
from Serotec. Binding was detected with isotype specific antisera: goat anti-rabbit TRITC and goat anti-mouse 
IgG1-FITC (both from Southern Biotechnology, Cambridge, UK). For analysis of immunologically-relevant 
cells in colonic lamina propria, the monoclonal antibodies used were: anti-porcine CD16 (clone G7, IgG1); 
anti-porcine CD4 (clone MIL17, IgG2b); anti-porcine MIL11 (an endothelial cell-associated molecule, IgE62); 
anti-porcine MHCII DR (clone MSA3, IgG2a) (all from Serotec). Binding was detected with isotype specific 
antisera: goat anti-mouse IgG1-TRITC; goat anti-mouse IgG2b-FITC; biotinylated rat anti-mouse IgE detected 
with AMCA-Strepavidin (Vector Laboratories); goat anti-mouse IgG2a AF633 (all Southern Biotechnology). 
Non-specific binding was prevented by 5% pig serum, 5% goat serum and 5% rat serum in PBS. Slides were 
mounted using Vectashield (Vector Laboratories). Negative control slides were prepared in conjunction with 
each positive slide.
Images were captured using a Leica DMR-B fluorescence microscope fitted with appropriate fluorescence 
filters. 10 greyscale, high quality 16-bit TIFF images were acquired using a x20 objective lens for each tissue sam-
ple (60 images/treatment group and 60 images/batch) using a Leica DC350FX camera and TWAIN-compliant 
software (Leica). The area of tissue staining positively with each antibody, or combination of antibodies, was 
quantified as we have described previously50 using ImageJ version 1.4463. Briefly, either the lamina propria (anti-
gen presentation analysis) or epithelium (TCJ analysis) was outlined and identified as the region of interest in 
each image. A specifically design MACRO was used to generate a binary image of positive staining for each of 
the individual channels and the proportion of positive pixels for each channel, and for each of the 12 possible 
combinations was recorded.
Data Analysis. For intestinal TCJ analysis following B. lactis NCC2818 supplementation, univariate linear 
regression was carried out using piglet as the experimental unit and litter, tissue and probiotic treatment as vari-
ables. Individual differences between treatment groups were determined by least-significant differences as in our 
previous experiments37. For intestinal TCJ analysis of the replicate batches, born 8 weeks apart, litter could not 
be used as a variable.
NMR analysis was carried out as previously described53. Orthogonal partial least squares discriminant analysis 
(O-PLS-DA) was performed in a Matlab environment using in-house algorithms64. To generate the serum trajec-
tory, a series of pair-wise O-PLS-DA models were constructed at each time-point using unit variance (uv) scaling 
and the cross-validated scores (Tcv) were extracted for each model. The Tcv were then normalised by dividing 
each value by the standard deviation of the cumulative Tcv for each model, and the mean Tcv (+/− standard 
deviation) plotted over time. For each O-PLS-DA model showing urinary, microbial, cytokine or immunoglob-
ulin differences, it was determined whether the Q2Y value (predictive ability) of the model was significantly dif-
ferent to the Q2Y value calculated from up to 2,000 random permutations of Y using the cumulative probability 
value determined at the 95th quartile (in-house algorithm written by Dr. O.Cloarec). Models were uv scaled such 
that each variable had equal weight in the model, and were subject to a 7-fold cross-validation step. Correlation 
coefficients of >+/−0.6 (r) or >0.4 (r2), determined by the Pearson Product-Moment coefficient as being signif-
icant at the 95% confidence interval, are highlighted in the Figures. Metabolites of interest were integrated using 
an in-house routine (written by R. Cavill).
Statistical analysis of 4 colour quantitative immunofluorescence was carried out using Factor Analysis in SPSS 
version 16 statistics (IBM SPSS inc, Chicago, US) using the proportion of pixels positive and negative for all com-
binations of CD4, CD16, MIL11 and MHCIIDR as variables (16 in total).
For the immuno-metabolic interactions, the NMR matrix was tested against each immunological parameter 
using an orthogonal partial least squares approach (O-PLS), using the NMR matrix as the X matrix and each 
immunological parameter as the Y matrix. Parameters that were found to be significantly associated (p < 0.05) 
with the NMR data were extracted and the metabolites associated with the model highlighted.
Data availability. Data will be made available upon request.
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